WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H326928
CAS#: 129927-33-9 (HCl)
Description: Temiverine, also known as NS-21, is an anticholinergic drug with calcium antagonistic activity for the treatment of urinary frequency and urinary incontinence. NS-21 increases bladder capacity at lower doses in hypogastric nerve-transected rats than in sham-operated rats. NS-21 increases the bladder capacity without suppressing micturition pressure, suggesting that NS-21 may be a more effective therapeutic drug than propiverine, oxybutynin or flavoxate for the treatment of urinary frequency and urinary incontinence.
Hodoodo Cat#: H326928
Name: Temiverine hydrochloride
CAS#: 129927-33-9 (HCl)
Chemical Formula: C24H36ClNO3
Exact Mass: 0.00
Molecular Weight: 422.006
Elemental Analysis: C, 68.31; H, 8.60; Cl, 8.40; N, 3.32; O, 11.37
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 173324-94-2 (free base) 129927-33-9 (HCl) 791115-04-3 (HCl hydrate)
Synonym: NS-21; NS 21; NS21; Temiverine. CCRIS 7921; Brande name: Urespan.
IUPAC/Chemical Name: 5-(diethylamino)-2-methylpent-3-yn-2-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate hydrochloride
InChi Key: JQCLFZVNMLALLU-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H35NO3.ClH/c1-5-25(6-2)19-13-18-23(3,4)28-22(26)24(27,20-14-9-7-10-15-20)21-16-11-8-12-17-21;/h7,9-10,14-15,21,27H,5-6,8,11-12,16-17,19H2,1-4H3;1H
SMILES Code: O=C(OC(C#CCN(CC)CC)(C)C)C(O)(C1CCCCC1)C2=CC=CC=C2.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# 173324-94-2 (Temiverine) 129927-33-9 (Temiverine hydrochloride) 791115-04-3 (Temiverine hydrochloride hydrate)
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 422.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Nakamura A, Hirota T, Morino A, Imaoka S, Funae Y, Yamamoto Y, Tasaki T, Masuda M, Kazusaka A, Fujita S. Cytochrome P450 isoforms responsible for the N-deethylation and cyclohexane-hydroxylation of NS-21. Xenobiotica. 1999 Mar;29(3):243-52. PubMed PMID: 10219965.
2: Natsukawa T, Matsuzaki T, Hayashi S, Ukai Y, Yoshikuni Y, Kimura K. Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs. Gen Pharmacol. 1998 Jan;30(1):137-42. PubMed PMID: 9457495.
3: Hamada K, Sasaki Y, Taniguchi N, Fukui H, Miyatsuka Y, Kimura Y, Ukai Y, Yoshikuni Y, Kimura K. Anticholinergic and calcium antagonistic activities of NS-21 contribute to the inhibition of rat urinary bladder contractions. Gen Pharmacol. 1997 Nov;29(5):771-8. PubMed PMID: 9347324.
4: Sasaki Y, Hamada K, Yamazaki C, Seto T, Kimura Y, Ukai Y, Yoshikuni Y, Kimura K. Effect of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency. Int J Urol. 1997 Jul;4(4):401-6. PubMed PMID: 9256331.
5: Hayashi S, Natsukawa T, Ukai Y, Yoshikuni Y, Kimura K. Inhibitory effects of NS-21, a novel drug for urinary incontinence, and its active metabolite, RCC-36, on L-type calcium currents in isolated guinea pig detrusor smooth muscle cells. Naunyn Schmiedebergs Arch Pharmacol. 1997 May;355(5):659-66. PubMed PMID: 9151307.
6: Hayashi S, Natsukawa T, Suma C, Ukai Y, Yoshikuni Y, Kimura K. Cardiac electrophysiological actions of NS-21 and its active metabolite, RCC-36, compared with terodiline. Naunyn Schmiedebergs Arch Pharmacol. 1997 May;355(5):651-8. PubMed PMID: 9151306.
7: Okasaki K, Nagata R, Ohnishi M, Samejima H, Fujisawa H, Kimura K. [Antigenicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence]. J Toxicol Sci. 1997 Apr;22 Suppl 1:307-13. Japanese. Erratum in: J Toxicol Sci 1997 Nov;22 Suppl 2:435. PubMed PMID: 9170617.
8: Hatch RC, Regan KS, Ishibashi S, Nakazawa M, Iwakura K, Sumi N. Two-year dietary carcinogenicity study of (+/-)-4-diethylamino-1, 1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in rats. J Toxicol Sci. 1997 Apr;22 Suppl 1:289-306. PubMed PMID: 9170616.
9: Hatch RC, Regan KS, Ishibashi S, Nakazawa M, Iwakura K, Sumi N. Seventy-eight-week dietary carcinogenicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice. J Toxicol Sci. 1997 Apr;22 Suppl 1:275-87. PubMed PMID: 9170615.
10: Tamura H, Yamashita Y, Kitayama E, Iwakura K, Watanabe M, Sumi N. [Mutagenicity studies of RCC-36, the active metabolite of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence]. J Toxicol Sci. 1997 Apr;22 Suppl 1:263-74. Japanese. Erratum in: J Toxicol Sci 1997 Nov;22 Suppl 2:435. PubMed PMID: 9170614.
11: Otsuka M, Kajiwara Y, Ajimi S, Shimazaki H, Kikuno T, Ogura S, Inai T, Kakimoto K, Tamura H, Watanabe M, Sumi N. [Mutagenicity studies of (+/-)-4-diethylamino-1,1,-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence]. J Toxicol Sci. 1997 Apr;22 Suppl 1:251-61. Japanese. PubMed PMID: 9170613.
12: Schardein JL, York RG, Ninomiya H, Watanabe M, Sumi N. [Reproductive and developmental toxicity studies of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence (4). Perinatal and postnatal study in rats by oral administration]. J Toxicol Sci. 1997 Apr;22 Suppl 1:239-49. Japanese. PubMed PMID: 9170612.
13: Schardein JL, York RG, Ninomiya H, Watanabe M, Sumi N. [Reproductive and developmental toxicity studies of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence (3). Teratogenicity study in rabbits by oral administration]. J Toxicol Sci. 1997 Apr;22 Suppl 1:229-37. Japanese. PubMed PMID: 9170611.
14: Schardein JL, York RG, Ninomiya H, Watanabe M, Sumi N. [Reproductive and developmental toxicity studies of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence (2). Teratogenicity study in rats by oral administration]. J Toxicol Sci. 1997 Apr;22 Suppl 1:213-28. Japanese. PubMed PMID: 9170610.
15: Schardein JL, York RG, Ninomiya H, Watanabe M, Sumi N. [Reproductive and developmental toxicity studies of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence (1). Fertility study in rats by oral administration]. J Toxicol Sci. 1997 Apr;22 Suppl 1:201-12. Japanese. PubMed PMID: 9170609.
16: Ishibashi S, Nakazawa M, Tawaratani T, Yoshida M, Tamura H, Adachi T, Kawaguchi K, Iwakura K, Sumi N, Wakabayashi K. [The mechanism of increased thyroidal function caused by (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, administration in rats]. J Toxicol Sci. 1997 Apr;22 Suppl 1:187-99. Japanese. PubMed PMID: 9170608.
17: Nakazawa M, Kitayama E, Adachi T, Yoshida M, Ishibashi S, Yoshikawa K, Kajihara T, Iwakura K, Sumi N. [Toxicokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice and rats during 13-week dietary administration]. J Toxicol Sci. 1997 Apr;22 Suppl 1:177-85. Japanese. Erratum in: J Toxicol Sci 1998 Oct;23 Suppl 4:664-9. PubMed PMID: 9170607.
18: Yoshida M, Kawaminami A, Tawaratani T, Ishibashi S, Nakazawa M, Kitayama E, Oka T, Adachi T, Iwakura K, Sumi N. [A 12-month oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in dogs followed by a 2-month recovery test]. J Toxicol Sci. 1997 Apr;22 Suppl 1:147-75. Japanese. Erratum in: J Toxicol Sci 1997 Nov;22 Suppl 2:435. PubMed PMID: 9170606.
19: Yoshida M, Oka T, Tawaratani T, Ishibashi S, Nakazawa M, Kitayama E, Adachi T, Iwakura K, Sumi N. [A 13-week oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in dogs followed by a 5-week recovery test]. J Toxicol Sci. 1997 Apr;22 Suppl 1:125-46. Japanese. PubMed PMID: 9170605.
20: Furukawa S, Kouyama H, Kikumori M, Taniguchi Y, Nishimori T, Ishibashi S, Iwakura K, Sumi N. [Oral single-dose and 13-week repeat-dose toxicity studies of RCC-36, the active metabolite of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, in rats]. J Toxicol Sci. 1997 Apr;22 Suppl 1:93-124. Japanese. Erratum in: J Toxicol Sci 1997 Nov;22 Suppl 2:435. PubMed PMID: 9170604.
